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Abstract
Background: Giardia parasites cause gastrointestinal disease in humans, dogs, and many other animals worldwide.
The treatment of dogs for giardiasis requires further investigation to ascertain levels of drug efficacy and the possibility
of adverse side effects. Nitazoxanide (NTZ) has shown good clinical anti-Giardia activity in humans, yet it has not been
evaluated for the treatment of giardiasis in dogs.
Methods: Thirty-five dogs, naturally infected with Giardia were divided into five groups (n = 7): dogs in group
NTZ1, NTZ2, and NTZ3 were treated with a single oral dose of 37.5 mg/kg, 75 mg/kg, and 150 mg/kg, respectively, of NTZ
on days 0 and 14. The fourth group was treated with a commercially available regimen that includes a combination of
pyrantel, praziquantel, and febantel (FEB) administered orally for three consecutive days. Additionally, an untreated control
group was established. Giardia cysts from the stool of each dog were quantified on days -3, 0, 5, 7, 9, 11, 14, 18, 25, and
28. Biochemical parameters were evaluated in all dogs, before the first treatment and after concluding the experiment.
Results: Shedding of Giardia cysts was reduced in all treated groups when compared to untreated controls
(P < 0.01). However, NTZ2, NTZ3, and FEB had a lower risk during the study. Furthermore, NTZ was also effective against
another protozoan, Cryptosporidium spp. at doses of 75 mg/kg and 150 mg/kg, in contrast to the combination
of febantel + pyrantel + praziquantel. Biochemical parameters of treated animals, namely, aspartate transaminase and
alanine transaminase enzymes, remained within physiological ranges.
Conclusions: Based on these results, the implementation of NTZ as a treatment for giardiasis in dogs is proposed. The
administration of a single dose is an important advantage of NTZ because it reduces workload, particularly in animals
placed in shelters and kennels, where handling of large numbers of animals is required, and personnel is frequently
scarce.
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Background
Canine giardiasis is caused by isolates of Giardia from
four of the eight recognized genetic assemblages [1]. Of
these, assemblage A and B have zoonotic potential [2].
Giardia has been described as the most commonly found
parasite in dogs [3], though many infections are sub-
clinical and remain undetected. Cysts and trophozoites
of Giardia are shed in the faeces of all infected hosts
[4], contaminating food, water, and the environment
[5, 6]. Once a cyst has been ingested by a susceptible
host, two trophozoites are released within the small
intestine that will either remain free in the intestinal
lumen or adhere to enterocytes causing damage to the
microvilli and inducing the clinical signs of the infec-
tion. Trophozoites differentiate into cysts as they near
the colon, completing their life-cycle in approximately
8 days [7]. Giardiasis is associated with a wide range
of clinical signs, from diarrhea and malabsorption to a
mild gastrointestinal discomfort [8]. However, it has
been stated that giardiasis should be treated in all
positive dogs so that they do not remain a source of
infection for other animals and humans [2].
Although not approved by many regulatory agencies,
such as Food and Drug Administration (FDA), metronida-
zole is one of the most commonly used drugs to treat
giardiasis in dogs [9]. The use of tinidazole, a derivative of
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metronidazole, has also been reported [10], yet it is un-
available in many countries. Adverse drug effects are
common with these agents and include nausea, vomiting,
diarrhea, general discomfort, and loss of appetite [11].
Fenbendazole and febantel possess activity against Giardia
[10]. Albendazole has also been used to control this para-
site, but bone marrow suppression has been associated
with the use of this benzimidazole derivative in dogs and
cats [12, 13]. There are other drugs with giardicidal
activity, such as furazolidone, which can cause hemolysis
in individuals with a deficiency in the glucose 6-phosphate
dehydrogenase enzyme. Quinacrine is another available
giardicidal compound, though it is poorly tolerated be-
cause it causes nausea, vomiting, and cramps [14]. Para-
momycin is another potential giardicidal compound, but
there is limited information on its use [15–18]. While
metronidazole has been regarded as the drug of choice for
treating giardiasis, resistance has been documented in
human cases of Giardia infection, possibly due to mecha-
nisms that allow the protozoan to tolerate the oxidative
stress caused by this drug [9].
Nitazoxanide (NTZ) is a relatively new drug that was
approved by FDA in 2014 for the treatment of giardiasis
in humans. It is also effective against Trichomonas spp.,
Entamoeba histolytica, Clostridium difficile, Clostridium
perfringens, Helicobacter pylori, and Campylobacter
jejuni [19]. It has been shown that NTZ has a similar
efficacy for eliminating Giardia when compared to metro-
nidazole, but has fewer adverse effects [20–23]. To the
best of our knowledge, there are no formal studies on the
effect of NTZ against clinical infections of Giardia in
dogs. Therefore, the current trial was carried out to assess




Nitazoxanide (assigned purity, 99.53%) was kindly supplied
by Shin Yang–Hangzhou, Shinyang Samwoo Fine Chemical
CO. (Ningbo, China). Differential scanning calorimetric
(DSC), infrared absorption spectroscopy, and 1H and 13C
nuclear magnetic resonance spectroscopy revealed a lack of
impurities. A 30% suspension was made using sodium
benzoate, sucrose, xanthan gum, microcrystalline cellulose
and carboxymethylcellulose sodium, anhydrous citric acid,
sodium citrate dihydrate, acacia gum, sugar syrup, FD&C
Red #40 and Artificial Powdered Meat Flavor PC-0170 (PF
Inc., Florida, USA).
Animals
The work was carried out adhering to the guidelines of
the Institutional Committee for Use and Care of Experi-
mental Animals of the institution, according to the
Mexican Official Regulation NOM-062-ZOO-1999 [24].
Sixty-five dogs, selected from a shelter in Texcoco, State
of Mexico, Mexico, were screened for the presence of
Giardia by microscopic examination of faeces after zinc
sulfate centrifugation before the commencement of the
study. Initially, 40 animals were included as they tested
positive to Giardia on three occasions before the trial.
Dogs infected with pathogens other than gastrointestinal
parasites, as well as those with other ailments were
excluded from the study. Dogs shedding fewer than 10
Giardia cysts per examined slide were excluded from
the trial. Thus, 14 male and 21 female dogs, 1.42 ±
0.5 years old on average and weighing 14.4 ± 2.5 kg
(average) were included in this study. All dogs had lived
in the shelter for more than 3 months and had not
received any antiparasitic treatment in at least 3 months.
Upon their arrival to the shelter, they were treated with
a single dose of oxibendazole and niclosamide paste
(Vitaminthe® Reforzado, Virbac, Mexico). Animals were
allocated to individual rooms (1.5 × 3.0 m), separated
from each other with wire mesh and with 70% humidity.
They were fed commercial food without nutraceuticals
(Ol’ Roy Adulto, México) ad libitum, had free access to
water and soft bedding. The enclosures were cleaned
daily and the dogs’ comfort was ensured.
Experimental design
A randomized non-inferiority study was conducted for
the treatment of canine giardiasis, comparing the effi-
cacy of three different doses of nitazoxanide adminis-
tered every 14 days, to that of a FDA-approved reference
antiparasitic product containing pyrantel embonate,
febantel and praziquantel (Drontal Plus®, Bayer Animal
Health, Mexico) administered for three consecutive days
according to the manufacturer’s recommended dosage.
The giardicidal efficacy of the investigational product
was required to be equal to the reference product to
achieve non-inferiority.
This trial was conducted according to the guidelines of
the World Association for the Advancement of Veter-
inary Parasitology (WAAVP) for dose determination
studies. This document states that one internationally
accepted design includes a minimum of three groups
receiving different dosages of the investigational drug
together with an untreated control group [25]. Nita-
zoxanide has been experimentally administered to
Giardia-infected dogs previously at an oral dose of
25 mg/kg twice a day, with no efficacy, as 37.5 to 50%
of dogs that completed the experimental protocol,
remained positive for Giardia [26]. Considering that
50 mg/kg/day was not effective against giardiasis in
dogs, a dose of 75 mg/kg was selected, hoping to
achieve a greater efficacy. Furthermore, previous ex-
periments tested the anthelmintic efficacy of NTZ or-
ally administered to dogs at a dose of 75–200 mg/kg,
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and a high efficacy against cestodes and nematodes
was obtained [27].
All dogs were weighed on an electronic scale before treat-
ment and blood samples were collected for hematological
and biochemical analysis before drug dosing and 2 days
after the last treatment. For allocation purposes, systematic
random sampling was used. Animals were ranked from
lowest to highest Giardia cyst count determined on day
zero (0) before treatments and assigned to one of the five
groups (n = 7).
Groups 1 (NTZ1), 2 (NTZ2), and 3 (NTZ3) were treated
orally with the nitazoxanide paste preparation at a dose of
37.5 mg/kg, 75 mg/kg, or 150 mg/kg, respectively, on days
0 and 14 of the trial. The FEB group received the FDA-
approved reference commercial antiparasitic product for-
mulated as a tablet, which included a dose of 15 mg/kg of
febantel, 5 mg/kg of praziquantel, and 14.4 mg/kg of pyran-
tel embonate (Drontal Plus®, Bayer Animal Health, Mexico)
on days 0, 1, and 2 of the experiment, as recommended by
the manufacturer. An untreated control group (CTRL) was
also established, and received a placebo paste that con-
tained the following excipients: sodium benzoate, sucrose,
xanthan gum, microcrystalline cellulose and carboxymeth-
ylcellulose sodium, anhydrous citric acid, sodium citrate
dihydrate, acacia gum, sugar syrup, FD&C Red #40 and
artificial powdered meat flavor PC-0170. All dogs were
observed for 6 h after treatment for vomiting or other
adverse reactions.
In accordance with the guidelines of WAAVP, [10,
25, 28], three fecal samples were examined by micro-
scopic examination after zinc sulfate centrifugation
to determine the presence of Giardia cysts 3 days
before administering the drugs, as well as the day
that treatments were administered (Day 0) and on
days 5, 7, 9, 11, 14, 18, 25 & 28 [29]. The number
of Giardia cysts per slide was quantified by micros-
copy and cyst scores (0–4) were determined as follows: 0
= 0 cysts per slide; 1 = 1–100 cysts per slide; 2 = 100–300
cysts per slide; 3 = 300–500 cysts per slide; 4 = TNTC (too
numerous to count) per 10× objective field [30, 31].
Additionally, the flotation technique was conducted
to detect Cystoisospora oocysts and nematode eggs.
The Graham and Kinyoun techniques were carried
out to detect Dipylidium caninum egg packets or
Cryptosporidium oocysts, respectively [32, 33]. To
exclude a subjective decision, each sample was ana-
lyzed by three trained technicians in coprological
diagnosis.
Fecal consistency was determined on days 0, 5, 7, 9,
11, 14, 18, 25 and 28, according to the following scale: 1
= liquid diarrhea; 2 = doughy and shapeless; 3 = soft and
well-formed; 4 = hard, dry, firm, smooth and well-formed;
5 = very hard and dry [34, 35]. To avoid a biased in-
terpretation, three technicians that did not participate
in this study scored each individual sample to obtain
fecal consistency data.
Biochemical parameters
Serum samples were processed to determine concentra-
tions of aminotransferase alanine (ALT) and aspartate
aminotransferase (AST), measured using a diagnostic kit
(Spinreact, S.A. de C.V., Mexico) in a Cobas Mira
analyzer (Roche, S.A. de C.V., Mexico), according to the
manufacturer’s instructions.
Statistical analysis
Results were adjusted with generalized linear models,
and with maximum likelihood estimation methods [36].
Odds ratios were also estimated for the analysis of cyst
and faecal categories for each treatment against the control
group. An ordinal logit regression model was constructed
to allow a better understanding of the study variables (cyst
scores and faecal consistency).
Results
Odds ratios (OR) calculated vs the control group are
shown in Table 1. NTZ1, NTZ2, NTZ3 and FEB groups
displayed diminished risk of shedding Giardia cysts as
compared to untreated controls; yet NTZ2, NTZ3, and
FEB were less likely to excrete Giardia cysts during the
study (OR 0.559, 95% CI: 0.00–0.78, P = 0.001; OR 0.023,
95% CI: 0.015–0.036, P = 0.0001; OR 0.024, 95% CI:
0.015–0.038, P = 0.0001; OR 0.037, 95% CI: 0.024–0.038,
P = 0.0001; respectively).
No cysts were detected in the feces of groups NTZ2
and NTZ3 until day 11. On day 14, cysts were found in
stool samples from one dog of each of these two groups.
After the administration of NTZ to groups NTZ2 and
NTZ3 on day 14, no cysts were observed until the end
of the experiment. On the other hand, in the FEB group,
one dog shed Giardia cysts on days 9, 11, and 14 and
two dogs excreted no cysts on days 18, 25, and 28.
Nevertheless, no significant difference was obtained be-
tween NTZ2, NTZ3 and FEB groups (P > 0.05). It was
Table 1 Odds ratios (OR) and confidence intervals (CI) of cyst
scores for groups treated with, or without, nitazoxanide or with
pyrantel + praziquantel + febantel
Group OR (vs CTRL) 95% CI Times less than
control (1/OR)
P
NTZ1 0.559 0.00–0.78 1.8 0.001
NTZ2 0.023 0.015–0.036 43.5 0.0001
NTZ3 0.024 0.015–0.038 41.6 0.0001
FEB 0.037 0.024–0.038 27.0 0.0001
Abbreviations: NTZ1 group treated with 37.5 mg/kg nitazoxanide, NTZ2 group
treated with 75 mg/kg nitazoxanide, NTZ3 group treated with 150 mg/kg
nitazoxanide, FEB group treated with pyrantel + praziquantel + febantel, CTRL
untreated group
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also found that the administration of NTZ or febantel
did not result in different faecal consistencies in com-
parison to untreated controls.
Before the initiation of this trial, stool samples from all
dogs were screened to identify infections with other
parasites. Only Giardia-infected dogs were included in
the study. However, stool samples from these dogs
were positive for at least one of the following para-
sites: Cystoisospora spp., Cryptosporidium spp., Toxo-
cara canis, Ancylostoma caninum, Trichuris vulpis or
Dipylidium caninum. After an appropriate anthelmin-
tic treatment, no cestodes or nematodes were detected
in stool samples, while Cystoisospora oocysts were found
in all groups, as no anticoccidial drug was administered to
the experimental animals. As for the activity of NTZ
against other parasites, dogs treated with 75 mg/kg or
150 mg/kg did not shed Cryptosporidium oocysts; whereas
animals in NTZ1 or FEB groups remained infected with
this protozoan group (Table 2).
The therapeutic protocols used in this study did not
affect AST and ALT levels in any dog from NTZ1,
NTZ2, NTZ3, and FEB groups. Regarding the overall
health of experimental animals, vomiting occurred in a
single dog treated with 150 mg/kg nitazoxanide during
the treatment administration on day 14.
Discussion
Options for the treatment of giardiasis in dogs are limited,
and the few available drugs are often accompanied by ad-
verse reactions [12]. For example, it has been documented
that metronidazole administered to dogs at a rate of 22 mg/
kg, twice daily for 5 days, induces vomiting and neuro-
logical dysfunctions. Additionally, this drug has mutagenic
and carcinogenic potential [1, 37]. Albendazole has been
linked to vomiting, bloody diarrhea, abortion, and terato-
genicity [38]. Thus, the only available option at present for
the treatment of canine giardiasis is febantel; a drug usually
combined with praziquantel and pyrantel, administered for
three consecutive days, as in the FEB group in this trial.
This study indicates that the anti-Giardia activity of
75 mg/kg or 150 mg/kg NTZ or the combination of
antiparasitic drugs containing febantel, was similar. This
finding is consistent with previous reports that docu-
ment the giardicidal efficacy of febantel [28, 38, 39].
Nevertheless, results obtained in the present trial demon-
strate that cysts were recovered from the FEB-treated dogs
six days after the last treatment. This observation agrees
with previous studies that showed an increase in the num-
ber of dogs shedding cysts and the number of cysts shed
by dogs, beginning six days after treatment with this same
combination [38]. Other reports state that there appears
to be no significant improvement when febantel is given
to Giardia-infected dogs for three or five consecutive days
[28]. On the other hand, the administration of 75 mg/kg
or 150 mg/kg NTZ in the present study, halted the shed-
ding of Giardia cysts by dogs for 13 days. Hence, it is rea-
sonable to suggest that a single dose of NTZ at 75 mg/kg
or 150 mg/kg results in reduced shedding of cysts when
compared to febantel. In contrast, the data generated in
the present study shows a lack of a statistically significant
difference between cyst output in dogs that received a
single dose of NTZ at 37.5 mg/kg when compared to
untreated controls.
To the best of our knowledge, this is the first study to
confirm the high efficacy of NTZ for reducing Giardia
cyst shedding in dogs. A previous study documented
shedding of Giardia cysts in infected dogs five days after
the administration of NTZ at a dosage of 25 mg/kg two
times a day. [26]. In the present study, the cyst shedding
pattern of the NTZ1 (37.5 mg/kg) group was similar to
that of the untreated controls during the experiment. In
contrast, dogs that received a single dose of 75 mg/kg or
150 mg/kg, showed a reduction in cyst shedding. In this
case, the presence of parasite cysts after treating dogs
could be attributable to reinfection. Giardia has a short
prepatent period of 5 days and cysts are resistant to dis-
infectants and environmental conditions. These factors,
together with stress and the presence of cysts in the
animal’s fur, may explain reinfection [38].
Regarding the effect of the administration of NTZ or
febantel on faecal consistency, the results of this study do
not concur with previous findings, which demonstrated
that faeces could be shapeless to diarrheic in untreated
dogs as compared to febantel treated dogs [28]. However,
all Giardia-infected dogs were also infected with at least
one helminth or protozoan, such as Cystoisospora spp.
which did not respond to NTZ treatment. Infections
caused by coccidia are associated with abnormal faecal
consistency and deterioration of faecal scores [40, 41].
The presence of coccidia in the stool of dogs could
account for the abnormal consistency of stool specimens
despite anti-Giardia treatment, supporting the hypothesis
of the potential significance of cystoisosporosis as an asso-
ciated cause of diarrhea in dogs. One major limitation of
this study was the lack of an uninfected control group,
which could have confirmed the absence of a clear
association between fecal consistency and Giardia in-
fection [42–45].
In addition to the observed giardicidal activity of nita-
zoxanide administered at 75 mg/kg or 150 mg/kg, anti-
Cryptosporidium activity was observed. This finding
coincides with data reported in previous experiments,
which demonstrated that nitazoxanide dosages ranging
from 50 to 250 mg/kg reduce Cryptosporidium oocyst
excretion in laboratory animals and goats [46]. It should
be noted that nitazoxanide is the only drug approved by
the FDA in humans, as a treatment option for crypto-
sporidiosis [47].
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Table 2 Coccidia and helminths of dogs detected in feces before and after treatment with nitazoxanide (NTZ) or a combination of
pyrantel + praziquantel + febantel (FEB)
Group Dog Age
(years)
Parasite Day -3 Day 0 Day 14 Day 28
NTZ1 1 2 Cystoisospora sp. + + + +
Toxocara canis + – – –
2 1 Ancylostoma caninum + – – –
Toxocara canis + – – –
3 1 Cryptosporidium + + + +
Ancylostoma caninum + – – –
4 2 Dipylidium caninum + – – –
Toxocara canis + – – –
Ancylostoma caninum + – – –
5 2 Cystoisospora + + + +
Dipylidium caninum + – – –
Trichuris vulpis + – – –
6 2 Ancylostoma caninum + – – –
Trichuris vulpis + – – –
7 1 Cystoisospora + + + +
Cryptosporidium + + + +
Toxocara canis + – – –
Ancylostoma caninum + – – –
NTZ2 8 1 Cryptosporidium + + - -
Ancylostoma caninum + – – –
Trichuris vulpis + – – –
9 2 Cystoisospora + + + +
Toxocara canis + – – –
Dipylidium caninum + – – –
10 1 Ancylostoma caninum + – – –
Trichuris vulpis + – – –
11 1 Cystoisospora + + + +
Ancylostoma caninum + – – –
Toxocara canis + – – –
12 2 Cystoisospora + + + +
Trichuris vulpis + – – -
Dipylidium caninum + – – –
13 1 Cryptosporidium + + - -
Cystoisospora + – + +
Ancylostoma caninum + – – –
Dipylidium caninum + – – –
14 1 Ancylostoma caninum + – – –
Toxocara canis + – – –
Trichuris vulpis + – – –
NTZ3 15 1 Cystoisospora + + + +
16 1 Cryptosporidium + + - -
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Table 2 Coccidia and helminths of dogs detected in feces before and after treatment with nitazoxanide (NTZ) or a combination of
pyrantel + praziquantel + febantel (FEB) (Continued)
Cystoisospora + + + +
Toxocara canis + – – –
17 1 Ancylostoma caninum + – – –
Toxocara canis + – – –
Trichuris vulpis + – – –
Dipylidium caninum + – – –
18 1 Ancylostoma caninum + – – –
19 2 Cryptosporidium + + - -
Cystoisospora + + + +
Trichuris vulpis + – – –
20 2 Ancylostoma caninum + – – –
Trichuris vulpis + – – –
21 1 Cryptosporidium + + - -
Trichuris vulpis + – – –
Dipylidium caninum + – – –
FEB 22 2 Cryptosporidium + + + +
Dipylidium caninum + – – –
23 1 Cystoisospora + + + +
Toxocara canis + – – –
24 1 Cystoisospora + + + +
Ancylostoma caninum + – – –
Trichuris vulpis + – – –
25 1 Cryptosporidium + + + +
Ancylostoma caninum + – – –
26 1 Cryptosporidium + + + +
Ancylostoma caninum + – – –
Trichuris vulpis + – – –
27 1 Cystoisospora + + + +
Toxocara canis + – – –
Ancylostoma caninum + – – –
28 1 Toxocara canis + – – –
CTRL 29 2 Dipylidium caninum + – – –
Toxocara canis + – – –
Ancylostoma caninum + – – –
30 2 Cryptosporidium + + + +
Cystoisospora + + + +
Dipylidium caninum + – – –
Trichuris vulpis + – – –
31 1 Toxocara canis + – – –
Ancylostoma caninum + – – –
32 1 Cystoisospora + + + +
Toxocara canis + – – –
Ancylostoma caninum + – – –
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Dogs kept in kennels or shelters are more susceptible
to suffer from anorexia, anemia, and diarrhea caused by
gastrointestinal helminths and protozoans, given that
these places include young, old, and immunocom-
promised animals. Indeed, co-infection with several
intestinal parasites is frequently reported in kennels and
shelters, involving parasites such as Giardia, Toxocara
canis, Cryptosporidium spp., Ancylostoma caninum,
Capillaria aerophila [48], Toxascaris leonina, Uncinaria
stenocephala, Trichuris vulpis, Sarcocystis spp., capillariid
eggs [49, 50], and Cystoisospora spp. [51]. Therefore,
broad-spectrum drug formulations are most suitable in
these cases [41]. Indeed, NTZ administered at a dose of
75 mg/kg could represent a suitable drug for use under
these circumstances.
In this work, virtually no adverse reactions were
observed, much in agreement with other studies [23].
Vomiting occurred in one dog after the administration
of 150 mg/kg of NTZ. This result agrees with the study
by Basu et al. [52], who reported nausea in 9% of
patients treated with this compound. This may suggest that
the lower dose of 75 mg/kg is marginally safer, though
further research is required. In contrast, it has been pro-
posed that fenbendazole, the active form of febantel, may
promote liver tumors because it induces upregulation of
cytochrome P-450 isozymes (CYP) 2B1/2, which are in-
volved in hepatocarcinogenesis [53]. Finally, it is important
to reiterate that the therapeutic use of antiparasitic drugs in
kennels and shelters, should not be the only measure
employed to control these infections. Dog bathing and the
frequent cleaning and disinfection of their environment,
reduces the risk of infection and re-infection [28]. In fact,
studies have demonstrated that dogs re-shed cysts
following a brief period after antiparasitic treatment
when no disinfection or cleaning of their enclosures
is performed. Shampooing of dogs is recommended
because fecal material on the fur increases the chance
of reinfection [54–57].
The results of the current study suggest that adminis-
tration of 75 mg/kg of NTZ every 14 days is effective for
the treatment of giardiasis and cryptosporidiosis in dogs,
though this requires further evaluation.
Conclusions
This study demonstrates that the administration of 75 mg/
kg of NTZ every 14 days to dogs infected with Giardia
reduces cyst excretion. Data from this study will help in the
development of Giardia control programmes, particularly
in shelter animals.
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nitazoxanide, FEB group treated with pyrantel + praziquantel + febantel, CTRL untreated group
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